Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lasmiditan

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

Eli Lilly HQ

Lilly and Incyte’s baricitinib aces phase III trials

Supports its potential as a therapy for rheumatoid arthritis

- PMLiVE

Rivals look to put pressure on Sanofi’s Lantus

Novo Nordisk and Lilly claim clinical benefitsover top-selling diabetes drug

Lilly backs Bluetooth insulin device and app firm

Invests in San Diego-based medical device company Companion Medical

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

Teva Pharma logo

Teva says chronic migraine drug is ready for phase III

TEV-48125 efficacy “has not previously been achieved”

Eli Lilly HQ

Lilly and Sanford-Burnham reveal immunology collaboration

Will aim to discover and develop therapies in the field

Eli Lilly HQ

Lilly and BioNTech partner on cancer immunotherapy

Lilly gets on board with the hottest research ticket in town

- PMLiVE

Transition takes on Lilly muscle-boosting drug

Lilly to receive just $1m upfront but could get up to $100m in milestones

Sanofi reception

Poor Lantus sales sees Sanofi’s diabetes unit fall

French firm hit by insulin pricing pressures and soon faces biosimilar threat

- PMLiVE

BMS gives Erbitux rights to Lilly in the US

Firm wants to focus on its burgeoning PD-1 cancer range

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links